Here are 10 things to know:
1. The first quarter consolidated net revenues were up 5 percent over the same period last year.
2. International revenue grew 25 percent in constant currency over the first quarter of 2014 and represented 37 percent of global revenues as reported.
3. In the first quarter, the company launched the Arsenal spinal fixation system commercially in the United States, and received approval in Japan. The company also launched the Zodiac and Illico MIS in Brazil in April 2015.
4. The United States sales force’s plan to expand into new metro areas is more than 75 percent complete.
5. The European Union sales distribution expansion is 50 percent complete.
6. The Untied States net revenues were down in the first quarter 4.9 percent, reaching $30.5 million. International net revenues were up 6.2 percent to $18.2 million.
7. The consolidated gross profit was $32.9 million and gross margin was 67.7 percent.
8. The gross profit declined 1.1 percent from the first quarter of 2014, primarily due to the lower United States sales volume.
9. The company reiterated full year 2015 constant currency revenue growth guidance of around 4 percent to 7 percent over 2014, in the range of $215 million to $222 million.
10. The expected annual adjusted EBITDA of $34 million to $37 million, a 10 percent to 20 percent growth over last year.
More articles on orthopedic devices:
DJO Global’s early tender results in for exchange offer and consent solicitation
NuVasive to pay $13.8M in OIG agreement
Clinical trials, team growth, IPO—8 key notes on Bone Therapeutics’ 2014
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
